Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-04-02
2000-07-04
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
564282, 564283, A01N 3312
Patent
active
060839902
ABSTRACT:
The present invention discloses the use of permanently charged steroid agonists or antagonists as potent anti-angiogenic compositions comprising as an active ingredient a compound of the general formulae I, II or III: ##STR1## wherein DRUG is any steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist and the substituents are as defined in the specification.
REFERENCES:
patent: 2914561 (1959-11-01), Allen et al.
patent: 2914562 (1959-11-01), Allen et al.
patent: 2914564 (1959-11-01), Allen et al.
patent: 2971001 (1961-02-01), Palopoli et al.
patent: 4536516 (1985-08-01), Harper
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4973755 (1990-11-01), Grafe
Jarman et al., "Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts", Cancer Drug Design, 1, 259-268, 1986.
Jordan, "A current view of tamoxifen for the treatment and prevention of breast cancer", Br. J. Pharmacol. 110, pp. 507-517, 1993.
Dorland's Illustrated Medical Dictionary, 28th Edition, Apr. 1995, pp. 801, 1450 and 1576.
Br. J. Pharmacol. (1993), 110, 507-517, "A current view of tamoxifen for the treatmentand prevention of breast cancer," by V. Craig Jordan.
Cancer Drug Design (1986), 1,259,268, "Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts," by M. Jarman, et al.
Neuroscience Research 4, 65-99 (1971), "Site of Action and Active Form of Local Anesthetics," Toshio Narashashi, et al.
Endocrine Therapies of Cancer, "Cancer Chemotherapy," by Bruce A. Chabner et al. (1990).
Reports 1477, vol. 83, No. 20, Oct. 16, 1991, "Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroytamoxifen," by C. Kent Osborne et al.
Endocrinology, vol. 123, No. 4, 1747-1753, "Different Induction of Progestin-Binding Sites In Uterine Cell Types by Estrogen and Antiestrogen," by Bruce E. Ennis et al. (1988).
Eur J Cancer, vol. 29A, No. 4, 589-592, 1993, "Breast Cancer Chemoprevention," by Alberto Costa.
Annals of Medicine 25, 105-111, 1993, "Development of a Preclinical model for Hormonal Therapy of Human Endometrial Carcinomas," by P.G. Satyaswaroop.
Academic Press Limited, Cancer Treatment Reviews (1993), 19(Supplement B), 11-19, "Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse," by Phillippa G. de Takats, et al.
Endocrinology, 1986, vol. 119, No. 6, 2261-2669, Antiestrogen Action in the Medial Basal Hypothalamus and Pituitary of Immature Female Rates: Insights Concerning Relationships among Estrogen, Dopamine, and Prolactin, by Thomas W. Toney et al.
Journal of Endocrinology, 1991, 130, 409-414, "Pharmacological characterization of a novel oestrogen antagonist, ZK 119010, in rats and mice," by Y. Nishino et al.
Endocrinology, 1991, vol. 129, No. 3, 1568-1574, "Dose Dependent Effects of Tamoxifen on Long Bones in Growing Rats: Influence of Ovarian Status," by Lilly Y. Moon.
Biegon Anat
Brewster Marcus E.
Jones Dwayne C.
Pharmos Corporation
LandOfFree
Enhanced anti-angiogenic activity of permanently charged derivat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced anti-angiogenic activity of permanently charged derivat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced anti-angiogenic activity of permanently charged derivat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1487042